HEXOPRENALINE DIHYDROCHLORIDE

Details

Stereochemistry	MIXED
Molecular Formula	C22H32N2O6.2ClH
Molecular Weight	493.421
Optical Activity	UNSPECIFIED
Defined Stereocenters	0 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of HEXOPRENALINE DIHYDROCHLORIDE

Structure Search

SMILES

Cl.Cl.OC(CNCCCCCCNCC(O)C1=CC(O)=C(O)C=C1)C2=CC=C(O)C(O)=C2

InChI

InChIKey=LECFJMMCVCBLPN-UHFFFAOYSA-N

InChI=1S/C22H32N2O6.2ClH/c25-17-7-5-15(11-19(17)27)21(29)13-23-9-3-1-2-4-10-24-14-22(30)16-6-8-18(26)20(28)12-16;;/h5-8,11-12,21-30H,1-4,9-10,13-14H2;2*1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C22H32N2O6
Molecular Weight	420.4993
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	0 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789
Curator's Comment: description was created based on several sources, including, http://home.intekom.com/pharm/intramed/ipradinf.html

Hexoprenaline is a selective beta2-adrenoreceptor agonist indicated for use in the treatment of bronchospasm associated with obstructive airways diseases, including asthma, bronchitis and emphysema. In many countries the drug is used as tocolytic agent (under the trade name gynipral).

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 203 Target ID: CHEMBL210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789	Agonist 2678

Conditions

Condition	Modality	Highest Phase	Product
Asthma 241 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789	Palliative	Approved 8429	Unknown Approved Use Unknown
Bronchitis 51 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789	Primary	Approved 8429	Unknown Approved Use Unknown
Emphysema 13 Sources: http://www.ncbi.nlm.nih.gov/pubmed/195789	Primary	Approved 8429	Unknown Approved Use Unknown
Premature labour 10 Sources: https://www.medicinep.com/gynipral-tocolytic-uterorelaxant-637.html	Preventing	Approved 8429	GYNIPRAL Approved Use Gynipral prevents threatened abortion with premature labour.

PubMed

Title	Date	PubMed
Hexoprenaline: a review of its pharmacological properties and therapeutic efficacy with particular reference to asthma.	1977 Jul	195789
[Tocolysis with hexoprenalin and salbutamol in a clinical comparison].	1983 Mar	6552999
The effects of fetal breathing movements on the utero-fetal-placental circulation.	2001 Jan	11753512
Flow injection potentiometric assay of hexoprenaline in its pure state, pharmaceutical preparations, and biological samples.	2008	18483573
Management of foetal asphyxia by intrauterine foetal resuscitation.	2010 Sep	21189876

Sample Use Guides

In Vivo Use Guide

Hexoprenaline can be given by metered aerosol in doses of 200 to 400μg, up to 5 times daily (in asthma), or as an infusion of 0,30 ug and 0,45 ug per minute or as 1-2 tablets q.i.d (0.5 mg per tablet) (maintenance dose in premature labour).

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Sat Dec 16 07:50:46 UTC 2023` Edited by `admin` on `Sat Dec 16 07:50:46 UTC 2023`
Record UNII	97TDI0239I
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HEXOPRENALINE DIHYDROCHLORIDE

Common Name

English

Hexoprenaline hydrochloride [WHO-DD]

Common Name

English

HEXOPRENALINE HYDROCHLORIDE

Common Name

English

HEXOPRENALINE HCL

Common Name

English

HEXOPRENALINE DIHYDROCHLORIDE [MI]

Common Name

English

BENZYL ALCOHOL, .ALPHA.,.ALPHA.'-(HEXAMETHYLENEBIS(IMINOMETHYLENE))BIS(3,4-DIHYDROXY-, DIHYDROCHLORIDE

Common Name

English

Code System Code Type Description

SMS_ID

100000128147